Equities

Ikapharmindo Putramas Tbk PT

IKPM:JKT

Ikapharmindo Putramas Tbk PT

Actions
Consumer Staples Personal Care, Drug and Grocery Stores
  • Price (IDR)248.00
  • Today's Change-2.00 / -0.80%
  • Shares traded2.63m
  • 1 Year change--
  • Beta--
Data delayed at least 10 minutes, as of May 20 2024 10:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PT Ikapharmindo Putramas Tbk. is an Indonesia-based company, which is engaged in the marketing of pharmaceutical products and consumer health products located in Jakarta, Indonesia. The Company operates through two segments: Non Pharma, Pharma, and Contract manufacturing. The Company is focused on a diverse portfolio for the Indonesian market, with brands in the pharmaceutical product categories of prescription medicines, over the counter (OTC), nutraceuticals, professional hair care products and baby products. Its prescription pharmaceuticals include neurology, dermatology, gastroenterology, and cardiology. Its consumer division products consist of professional and retail haircare products, and also Baby HUKI, which consists of baby bottles and pacifiers, and other baby feeding equipment.

  • Revenue in IDR (TTM)--
  • Net income in IDR--
  • Incorporated1978
  • Employees983.00
  • Location
    Ikapharmindo Putramas Tbk PTPulogadungJAKARTA TIMUR 13930IndonesiaIDN
  • Phone+62 214600086
  • Fax+62 214608865
  • Websitehttps://ikapharmindo.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Organon Pharma Indonesia Tbk PT2.86tn161.86bn144.17bn212.00----0.71680.050444,960.0244,960.02794,244.70246,656.201.886.008.1714,368,320,000.0010.6311.4116.0115.869.5912.575.666.781.1876.190.007--17.454.497.398.11-14.93--
Phapros Tbk PT1.01tn5.96bn406.56bn1.47k68.220.54247.410.40097.097.091,207.30892.300.56781.702.08688,012,000.000.33662.070.57484.0451.1251.790.59283.680.86421.050.5103---13.21-0.1734-78.77-46.21-24.81--
Ikapharmindo Putramas Tbk PT-100.00bn-100.00bn421.17bn983.00------------------------------------------------4.68--104.02------
Indofarma Tbk PT684.91bn-437.05bn762.42bn1.09k------1.11-141.03-141.03221.00-33.990.41473.143.13578,473,800.00-26.46-6.07-75.37-12.29-25.7314.39-63.81-5.630.4962-15.511.16---60.58-6.85-1,040.12---32.32--
Pyridam Farma Tbk PT702.07bn-85.22bn1.17tn1.19k--0.7264--1.66-34.19-34.19281.70143.180.46161.874.16588,489,200.00-5.606.31-6.968.0742.0642.56-12.148.831.170.02080.7343---1.8722.89-130.96--2.93--
Darya-Varia Laboratoria Tbk PT1.89tn146.34bn1.68tn1.27k11.481.207.990.8885130.66130.661,688.291,253.960.93351.913.011,490,061,000.007.228.459.5511.4151.5852.217.748.831.9651.880.001---1.362.16-2.03-6.1216.57--
Merck Tbk PT961.43bn178.24bn1.79tn390.0010.052.258.511.86397.85397.852,146.061,776.520.96361.508.082,465,215,000.0017.8612.7821.8518.1241.6540.5318.5414.062.73--0.0223---14.519.46-0.888436.67-3.13--
Data as of May 20 2024. Currency figures normalised to Ikapharmindo Putramas Tbk PT's reporting currency: Indonesian Rupiah IDR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.